Indications O
for O
early O
conversion O
were O
neurotoxicity B
( O
20 O
) O
, O
( B
insulin I
- I
dependent I
) I
diabetes I
mellitus I
( O
IDDM B
) O
( O
5 O
) O
, O
nephrotoxicity B
( O
3 O
) O
, O
gastrointestinal B
( I
GI I
) I
toxicity I
( O
6 O
) O
, O
and O
cardiomyopathy B
( O
1 O
) O
, O
and O
for O
late O
conversion O
were O
neurotoxicity B
( O
15 O
) O
, O
IDDM B
( O
12 O
) O
, O
nephrotoxicity B
( O
3 O
) O
, O
GI B
toxicity I
( O
5 O
) O
, O
hepatotoxicity B
( O
6 O
) O
, O
post B
- I
transplant I
lmphoproliferate I
disease I
( O

Indications O
for O
early O
conversion O
were O
neurotoxicity B
( O
20 O
) O
, O
( B
insulin I
- I
dependent I
) I
diabetes I
mellitus I
( O
IDDM B
) O
( O
5 O
) O
, O
nephrotoxicity B
( O
3 O
) O
, O
gastrointestinal B
( I
GI I
) I
toxicity I
( O
6 O
) O
, O
and O
cardiomyopathy B
( O
1 O
) O
, O
and O
for O
late O
conversion O
were O
neurotoxicity B
( O
15 O
) O
, O
IDDM B
( O
12 O
) O
, O
nephrotoxicity B
( O
3 O
) O
, O
GI B
toxicity I
( O
5 O
) O
, O
hepatotoxicity B
( O
6 O
) O
, O
post B
- I
transplant I
lmphoproliferate I
disease I
( O

CONCLUSIONS O
: O
Clinicians O
should O
be O
aware O
that O
fluconazole O
, O
even O
at O
low O
doses O
, O
may O
cause O
prolongation B
of I
the I
QT I
interval I
, O
leading O
to O
TDP B
. O

Intravenous O
ribavirin O
is O
the O
treatment O
of O
choice O
for O
infection B
with I
hemorrhagic I
fever I
viruses I
. O

Discriminating O
between O
primary O
SLE B
- O
induced O
affection B
of I
the I
musculoskeletal I
system I
and O
drug O
- O
induced O
side O
effects O
is O
important O
for O
appropriate O
treatment O
of O
SLE B
patients O
. O

Unfortunately O
, O
acute O
interstitial B
nephritis I
was O
irreversible O
and O
the O
patient O
developed O
end B
- I
stage I
renal I
disease I
. O

We O
present O
a O
15 O
- O
year O
- O
old O
girl O
schizophrenic B
who O
developed O
frequent O
involuntary B
eye I
- I
blinking I
movements I
after O
5 O
months O
of O
amisulpride O
treatment O
( O
1000 O
mg O
per O
day O
) O
. O

In O
summary O
, O
suprofen O
causes O
acute B
declines I
in I
renal I
function I
, O
most O
likely O
by O
directly O
altering O
the O
intrarenal O
distribution O
of O
uric O
acid O
. O

In O
order O
to O
investigate O
the O
effects O
of O
daidzein O
from O
Pueraria O
thunbergiana O
on O
scopolamine O
- O
induced O
impairments B
of I
learning I
and I
memory I
, O
we O
conducted O
a O
series O
of O
in O
vivo O
tests O
. O

Pilocarpine O
seizures B
cause O
age O
- O
dependent O
impairment B
in I
auditory I
location I
discrimination I
. O

Definition O
and O
management O
of O
anemia B
in O
patients O
infected B
with I
hepatitis I
C I
virus I
. O

Chronic B
infection I
with I
hepatitis I
C I
virus I
( O
HCV O
) O
can O
progress O
to O
cirrhosis B
, O
hepatocellular B
carcinoma I
, O
and O
end B
- I
stage I
liver I
disease I
. O

Any O
alcohol O
consumption O
postpregnancy O
recognition O
among O
the O
heavy O
drinkers O
resulted O
in O
reduced B
cerebellar I
growth I
as O
well O
as O
decreased B
cranial I
to I
body I
growth I
in O
comparison O
with O
women O
who O
either O
quit O
drinking O
or O
who O
were O
nondrinkers O
. O

Nonketotic B
hyperglycinemia I
is O
a O
disorder B
of I
amino I
acid I
metabolism I
in O
which O
a O
defect O
in O
the O
glycine O
cleavage O
system O
leads O
to O
an O
accumulation O
of O
glycine O
in O
the O
brain O
and O
other O
body O
compartments O
. O

The O
degree O
of O
vacuolar B
degeneration I
of I
myocardial I
cells I
was O
analyzed O
in O
relation O
to O
the O
duration O
of O
adriamycin O
treatment O
( O
2 O
mg O
/ O
kg O
, O
once O
a O
week O
) O
. O

Reverse O
or O
inverted O
left B
ventricular I
apical I
ballooning I
syndrome I
( O
reverse O
Takotsubo B
cardiomyopathy I
) O
in O
a O
young O
woman O
in O
the O
setting O
of O
amphetamine O
use O
. O

Transient O
left B
ventricular I
apical I
ballooning I
syndrome I
was O
first O
described O
in O
Japan O
as O
" O
Takotsubo B
cardiomyopathy I
. O
" O
This O
syndrome O
has O
been O
identified O
in O
many O
other O
countries O
. O

In O
the O
present O
case O
, O
complete O
atrioventricular B
( I
AV I
) I
block I
with O
syncopal B
attacks I
developed O
secondary O
to O
lithium O
therapy O
, O
necessitating O
permanent O
pacemaker O
implantation O
. O

Comparison O
of O
unilateral O
pallidotomy O
and O
subthalamotomy O
findings O
in O
advanced O
idiopathic B
Parkinson I
' I
s I
disease I
. O

A O
prospective O
, O
randomized O
, O
double O
- O
blind O
pilot O
study O
to O
compare O
the O
results O
of O
stereotactic O
unilateral O
pallidotomy O
and O
subthalamotomy O
in O
advanced O
idiopathic B
Parkinson I
' I
s I
disease I
( O
PD B
) O
refractory O
to O
medical O
treatment O
was O
designed O
. O

We O
report O
on O
an O
infant O
with O
multiple B
cranial I
- I
nerve I
involvement I
attributable O
to O
brainstem B
dysgenesis I
, O
born O
to O
a O
cocaine B
- I
addicted I
mother O
. O

National O
project O
on O
the O
prevention O
of O
mother O
- O
to O
- O
infant O
infection B
by I
hepatitis I
B I
virus I
in O
Japan O
. O

In O
Japan O
, O
a O
nationwide O
prevention O
program O
against O
mother O
- O
to O
- O
infant O
infection B
by I
hepatitis I
B I
virus I
( O
HBV O
) O
started O
in O
1985 O
. O

Intravenous O
injection O
of O
the O
specific O
platelet O
- O
activating O
factor O
( O
PAF O
) O
antagonist O
BN O
52021 O
( O
10 O
mg O
/ O
kg O
) O
, O
30 O
min O
before O
bupivacaine O
administration O
( O
2 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
suppressed O
both O
the O
decrease B
of I
MBP I
and I
HR I
. O

When O
BN O
52021 O
( O
20 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
was O
injected O
immediately O
after O
bupivacaine O
( O
2 O
mg O
/ O
kg O
) O
, O
a O
partial O
reversion O
of O
the O
decrease B
of I
MBP I
and I
HR I
was O
observed O
, O
whereas O
the O
dose O
of O
10 O
mg O
/ O
kg O
was O
ineffective O
. O

The O
rise B
in I
resting I
blood I
pressure I
with O
hydrocortisone O
is O
associated O
with O
an O
increased B
cardiac I
output I
( O
presumably O
due O
to O
increased O
blood O
volume O
) O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Pretreatment O
with O
type O
- O
2 O
serotonin O
antagonists O
may O
be O
clinically O
useful O
in O
attenuating O
opiate O
- O
induced O
rigidity B
, O
although O
further O
studies O
will O
be O
necessary O
to O
assess O
the O
interaction O
of O
possibly O
enhanced O
CNS O
, O
cardiovascular B
, I
and I
respiratory I
depression I
. O

Tiapride O
, O
a O
substituted O
benzamide O
derivative O
closely O
related O
to O
metoclopramide O
, O
reduced O
levodopa O
- O
induced O
peak O
dose O
involuntary B
movements I
in O
16 O
patients O
with O
idiopathic B
Parkinson I
' I
s I
disease I
. O

We O
documented O
airway O
occlusion O
during O
sleep O
and O
an O
abnormally O
high O
supraglottic O
resistance O
while O
awake O
in O
a O
54 O
- O
yr O
- O
old O
woman O
who O
had O
developed O
physical O
changes O
and O
the O
syndrome B
of I
obstructive I
sleep I
apnea I
while O
being O
administered O
exogenous O
androgens O
. O

Hepatic B
veno I
- I
occlusive I
disease I
caused O
by O
6 O
- O
thioguanine O
. O

This O
case O
presented O
a O
unique O
opportunity O
to O
observe O
the O
histologic O
features O
of O
clinically O
reversible O
hepatic B
veno I
- I
occlusive I
disease I
over O
time O
, O
and O
may O
be O
the O
first O
case O
of O
veno O
- O
occlusive O
related O
solely O
to O
6 O
- O
thioguanine O
. O

We O
describe O
such O
a O
case O
in O
a O
patient O
with O
end B
- I
stage I
renal I
disease I
( O
ESRD B
) O
maintained O
on O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
CAPD O
) O
. O

Prolongation B
of I
the I
QT I
interval I
related O
to O
cisapride O
- O
diltiazem O
interaction O
. O

Knowing O
that O
heart O
mitochondria O
represent O
almost O
40 O
% O
of O
heart O
muscle O
by O
weight O
, O
we O
conclude O
that O
the O
deteriorating O
effects O
of O
ADR O
on O
cardiovascular O
function O
involve O
mitochondrial B
structural I
and I
functional I
impairment I
. O

